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Abstract
MicroRNAs (miRNAs) are important components of cellular signaling pathways, acting either as pathway regulators or
pathway targets. Currently, only a limited number of miRNAs have been functionally linked to specific signaling pathways.
Here, we explored if gene expression signatures could be used to represent miRNA activities and integrated with genomic
signatures of oncogenic pathway activity to identify connections between miRNAs and oncogenic pathways on a high-
throughput, genome-wide scale. Mapping .300 gene expression signatures to .700 primary tumor profiles, we
constructed a genome-wide miRNA–pathway network predicting the associations of 276 human miRNAs to 26 oncogenic
pathways. The miRNA–pathway network confirmed a host of previously reported miRNA/pathway associations and
uncovered several novel associations that were subsequently experimentally validated. Globally, the miRNA–pathway
network demonstrates a small-world, but not scale-free, organization characterized by multiple distinct, tightly knit modules
each exhibiting a high density of connections. However, unlike genetic or metabolic networks typified by only a few highly
connected nodes (‘‘hubs’’), most nodes in the miRNA–pathway network are highly connected. Sequence-based
computational analysis confirmed that highly-interconnected miRNAs are likely to be regulated by common pathways to
target similar sets of downstream genes, suggesting a pervasive and high level of functional redundancy among
coexpressed miRNAs. We conclude that gene expression signatures can be used as surrogates of miRNA activity. Our
strategy facilitates the task of discovering novel miRNA–pathway connections, since gene expression data for multiple
normal and disease conditions are abundantly available.
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Introduction
MicroRNAs (miRNAs) are naturally occurring small RNA
molecules of ,22 nucleotides that negatively regulate gene
expression. Current models propose that miRNAs bind to
complementary sequences in the 39 untranslated regions (UTRs)
of target mRNAs, causing either target mRNA degradation or
reduced protein translation [1,2]. miRNAs play important roles in
cellular differentiation, proliferation, and apoptosis, and miRNA
deregulation has been implicated in cancer [1]. Emerging
evidence suggests that miRNAs can also play essential roles in
canonical signaling pathways, acting either as regulators of
pathway output or as important pathway targets [3,4,5]. For
example, a recent study has identified the miR-2355 cluster as a
critical regulator of the TGF-b signaling pathway [6]. However,
although hundreds of miRNAs have been discovered; to date only
relatively few miRNAs have been linked to specific signaling
pathways. Novel approaches are thus needed to accelerate the
identification of miRNA–pathway connections.
Attempts have been made to identify miRNA–pathway
relationships on a genome-wide scale [7,8,9]. However, most of
these previous studies have typically relied on DNA sequence-
based computational predictions, comparing lists of genes
predicted to be miRNA targets against gene sets of pathway
components and cellular functions (e.g. Biocarta and Gene
Ontologies). While informative, studies relying primarily on
miRNA target sequence predictions may suffer from the
limitations of current-generation sequence-based prediction algo-
rithms (e.g., TargetScanS, miRanda, and PITA) which have been
shown to produce excessively large numbers of false positives
among predicted miRNA target genes [10]. Studies purely based
on computational DNA sequence predictions also rarely incorpo-
rate actual experimental transcriptomic information, and thus
typically can neither determine if a particular miRNA is truly
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coexpressed miRNAs, in the same cell or tissue. Complementary
methodologies are thus needed to explore the true biological
diversity of miRNA–pathway relationships.
We, along with several others, have previously used gene
expression signatures to predict the activity of oncogenic signaling
pathways. In this approach, gene expression profiles of samples
exhibiting activation or repression of a specific pathway are
compared, producing a list of differentially-expressed genes as a
surrogate of that pathway’s activity. Once identified, this ‘‘pathway
signature’’ can then be subsequently mapped onto independent
samples from a wide diversity of disease conditions and tissues.
Expression signatures of pathway activity have been used to define
distinct subtypes of cancer ([11], uncover prevalently mutated
cancer pathways [12,13], and predict responses to targeted
therapies [14]. However, although the concept of using gene
expression signatures to predict signaling pathway activity is well-
established, to our knowledge no study has investigated if similar
signatures can also be used to predict patterns of miRNA activity.
In this study, we addressed this question and demonstrate that
gene expression signatures can indeed be used to predict the
activity status of specific miRNAs. By combining hundreds of
expression signatures representing pathways and miRNAs, we
created a miRNA–pathway network allowing the identification of
miRNA–pathway connections on a high-throughput, genome
wide scale. Notably, because our approach only requires gene
expression information, it is readily applicable to the thousands of
gene expression data sets currently available in the public domain.
Results
Gene Expression Signatures as Surrogates of miRNA
Activity
We conceived a strategy for generating gene expression
signatures representing miRNA activity (Figure 1A). First, a
training dataset is established comprising biological samples for
which both miRNA and mRNA gene expression profiles are
known. Second, to build a gene expression signature for any given
miRNA X, we chose biological samples where miRNA X was
either overexpressed (‘‘miRNA high’’ group; $ the 80th percentile
of all samples) or underexpressed (‘‘miRNA low’’ group; #20th
percentile). Each miRNA was analyzed independently. Third, we
used LIMMA (Linear Models for Microarray Data), a modified t-
test incorporating the Benjamini Hochberg multiple hypotheses
correction technique [15], to identify differentially expressed genes
(mRNAs) between the ‘‘miRNA high’’ and the ‘‘miRNA low’’
groups (significance level p,0.0001). These genes form a
candidate signature representing activity of that miRNA. Although
this approach requires an initial training data set for which
miRNA and mRNA are simultaneously available, this initial step
needs only to be done once - once the gene expression signature
representing the miRNA has been generated, this signature can
then be subsequently mapped against any cohort comprising only
mRNA expression information to infer miRNA activity in that
cohort.
For clarity, we define three terms that will be used in this study.
‘‘miRNA gene expression signature’’ will refer to a gene expression
based signature of miRNA activity. ‘‘miRNA gene expression
score’’ will be used to represent the level of miRNA activity
predicted by the miRNA gene expression signature, while the term
‘‘miRNA expression value’’ will refer to an actual experimentally
determined level of miRNA expression (e.g., measured using an
miRNA microarray).
We applied this approach on a training miRNA/mRNA
expression dataset of 43 gastric cell lines where each sample had
been profiled for expression of 799 miRNAs and 47,000 mRNA
transcripts (see Methods). Of the 799 miRNAs, we were able to
generate miRNA gene expression signatures for 516 miRNAs
(64.6%) above the threshold level of significance (p,0.0001). The
remaining 283 miRNAs were not analyzed further, as they were
not associated with sufficient numbers of samples in either the
‘‘miRNA high’’ or ‘‘miRNA low’’ groups for meaningful statistical
analysis. In this analysis, the minimum number of samples in
either the ‘‘miRNA high’’ or ‘‘miRNA low’’ groups was mandated
to be three, since this is the minimum number of samples required
for meaningful LIMMA analysis. There was no upper limit. The
516 miRNA signatures were then subjected to a robustness test to
select signatures passing a False Discovery Rate cutoff of ,5% (see
Methods, ‘‘Robustness of miRNA Gene Expression Signatures’’).
This operation resulted in a candidate set of 276 miRNA
signatures. The complete gene sets and size distributions of the
miRNA signatures are presented in Table S1 and Table S2.
To test the ability of the miRNA gene expression signatures to
act as surrogates of miRNA expression, we used a previously-
described signature mapping technique [11] (Methods and Text
S1). Specifically, we mapped the 276 miRNA gene expression
signatures onto an independent cohort of 31 primary gastric
tumors for which both miRNA and mRNA profiles were available.
In this validation analysis, a miRNA signature were deemed to be
significantly correlated to actual miRNA expression if the
signature was positively correlated to the miRNA (Spearman’s
correlation R.0) exceeding a threshold q-value of ,0.25, where
the q-value denotes the significance of the correlation (see
Methods). Using this criterion, more than a third of the miRNA
gene expression scores (101 out of 276 miRNA signatures,
36.59%) were positively correlated to their actual miRNA
expression values across the tumors (Spearman’s correlation
R.0, q,0.25) (Figure 1B, left panel). Figure 1C shows some
examples of miRNAs exhibiting good correlations between
miRNA gene expression scores and actual miRNA expression
Author Summary
MicroRNAs (miRNAs) are naturally occurring small RNA
molecules of ,22 nucleotides that regulate gene expres-
sion. Recent studies have shown that miRNAs can behave
as important components of cellular signaling pathways,
as pathway regulators or pathway targets. Currently
however, only a few miRNAs have been functionally linked
to specific signaling pathways, raising the need for novel
approaches to accelerate the identification of miRNA–
pathway connections. Here, we show that gene expression
signatures, previously used to reflect patterns of pathway
activation, can also be used to represent miRNA activities.
Using this approach, we constructed a genome-wide
miRNA–pathway network predicting the associations of
276 human miRNAs to 26 oncogenic pathways. The
miRNA–pathway network confirmed a host of previously
reported miRNA/pathway associations and uncovered
several novel associations that were subsequently exper-
imentally validated. Besides being the first study to
conceptually demonstrate that expression signatures can
act as surrogates of miRNA activity, our study provides a
large database of candidate pathway-modulating miRNAs,
which researchers interested in a particular pathway (e.g.
Ras, Myc) are likely to find useful. Moreover, because this
approach solely employs gene expression, it is immedi-
ately applicable to the thousands of microarray data sets
currently available in the public domain.
miRNA and Oncogenic Pathway Co-Activation Network
PLoS Genetics | www.plosgenetics.org 2 December 2011 | Volume 7 | Issue 12 | e1002415Figure 1. Gene expression signatures as surrogates of miRNA expression. A) Generating miRNA gene expression signatures. Differentially
expressed genes are identified between samples expressing high and low miRNA levels (nominal p,0.0001). B) Validation of miRNA gene expression
signatures (Validation Set #1:31 primary gastric tumors). (Left graph) Plot of Spearman correlations between miRNA gene expression scores and
miRNA expression values (pink) and corresponding q-values (blue). The black triangle highlights the number of miRNA signatures passing the R.0,
q,0.25 threshold. (Right graph) Distribution of miRNAs exhibiting positive correlations between miRNA gene expression scores and miRNA
expression values (R.0 and q,0.25), after the miRNA labels were randomly shuffled across 10000 permutations. The red arrow represents the
number of positively correlated miRNAs in the actual data. C) Examples of miRNAs in Validation set #1 showing high correlations between miRNA
gene expression scores and miRNA expression values. All p-values were corrected for multiple hypotheses (shown as q-values). D-F) Validation of
miRNA gene expression signatures in (D) Validation Set #2:578 ovarian carcinomas, (E) Validation Set #3:99 primary breast tumors, and (F) Validation
Set #4:418 glioblastomas. For Validation Sets #3 and #4, the numbers of miRNAs analyzed were limited to miRNAs present in both the gastric-
derived 276 miRNA signatures and miRNA expression data in the validation set.
doi:10.1371/journal.pgen.1002415.g001
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199b-5p, and hsa-miR-409-3p. To evaluate the likelihood that these
correlations might have been obtained by chance, we performed a
global permutation analysis where the miRNA labels were
scrambled in the primary tumor test set 10,000 times, and the
percentage of miRNAs exhibiting positive Spearman correlations
(R.0, q,0.25) between miRNA gene expression scores and
miRNA expression values were computed (see Methods). We
found that the number of miRNAs showing positive correlations
between miRNA expression values and miRNA expression scores
in the actual dataset (101 miRNAs) was consistently greater than
that obtainable in 10,000 randomly permuted data sets (i.e.,
p,0.0001, average number 42 per permutated data set)
(Figure 1B, right panel) (Table S3). This result indicates that it is
highly unlikely that the observed correlations between miRNA
gene expression scores and miRNA expression values are obtained
by chance alone.
To investigate the biological applicability of the gastric-derived
miRNA signatures beyond gastric cancer, we then analyzed three
additional independent validation sets for which gene expression
and miRNA data were available (Figures 1D–1F). In a series of
578 ovarian cancers (http://tcga-data.nci.nih.gov/tcga/tcga-
Home2.jsp), 61.96% (171 out of 276) of the gastric-derived
miRNA signature expression scores were positively correlated to
their actual miRNA expression values determined by a miRNA
microarray (threshold R.0; q-value q,0.25). Again, this
percentage was significantly greater compared to 10,000 randomly
permuted data sets (ie p,0.0001) (Figure 1D and Figure S1). In a
series of 99 breast tumors (GEO, GSE19783), 38.21% (94 of 246)
of the miRNA signature expression scores were positively
correlated to their actual miRNA expression values (p,0.0001)
(Figure 1E). Finally, in a series of 418 glioblastomas (http://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp), 33.33% (53 of 159) of the
miRNA expression scores were positively correlated to their actual
miRNA expression values (p=0.0059) (Figure 1F).
In a further comparison, we retrieved a signature based on
genes differentially expressed in hsa-miR-155-transfected HEK-293
cells compared to control cells (p,0.0005; GSE9264) [17], used it
to classify the two largest validation data sets (418 glioblastomas
and 578 ovarian cancers), and compared the classification to one
based on the gastric-derived hsa-miR-155 miRNA expression
scores. For both validation sets, there was either a highly
significant or near-significant concordance between tumors
assigned as ‘‘mir-155 positive’’ by the HEK293 signature and
those tumors assigned as ‘‘mir-155 positive’’ by the gastric-derived
hsa-miR-155 expression signature (p=5.861027 for glioblastoma
and p=0.06 for ovarian cancer; chi-square test) (Table S4). Taken
collectively, these results support the notion that miRNA gene
expression signatures can indeed recapitulate actual miRNA
expression patterns in a variety of tissues.
Gene Expression Signatures Identify miRNA–Pathway
Connections
To identify miRNA–pathway connections, we mapped the 276
miRNA gene expression signatures against a series of cancer
sample expression profiles. We then mapped onto the same
profiles 174 pathway signatures representing 26 oncogenic
pathways [11] (see Table S5 and Table S6 for the signatures
and their pathway assignments) (Figure 2A). Integrating the two
data sets, we computed correlations between the miRNA and
pathway gene expression signatures, identifying miRNAs either
positively or negatively correlated to the various pathways based
on a preset significance threshold (see Methods for details). To
focus on identifying robust miRNA–pathway connections, we
repeated the miRNA and pathway signature mapping across five
independent cancer cohorts – i) a panel of 39 gastric cancer cell
lines, ii) a cohort of 200 primary gastric tumors, iii) a second cohort
of 70 primary gastric tumors, iv) a cohort of 189 primary breast
tumors, and v) another cohort of 286 primary breast tumors. We
only retained those miRNA–pathway associations that a) did not
show any contradictions across the cohorts, and b) also existed in
the cell line cohort to facilitate subsequent in vitro validation studies
(see below). There was a wide range in the numbers of miRNAs
correlated to any particular pathway (5–262 miRNAs per
pathway, mean ,151 miRNAs, Table S7). Interestingly, the
reproducibility of microRNA-pathway associations did not appear
to be significantly influenced by the particular tissue type of the
cancer cohorts (Table S8), although we emphasize that this
certainly does not rule out the possibility that tissue-specific
miRNA effects may, and are indeed likely, to also exist (see
Discussion). A complete list of miRNA–pathway associations is
available in Table S9, and Table S10 provides a list of the top
miRNAs associated with the highest number of pathways.
We surveyed the identified miRNA–pathway interactions in the
context of several specific pathways. Supporting the biological
relevance of the predicted miRNA–pathway connections, we
observed several previously reported and experimentally validated
miRNA–pathway associations. A few examples are now presented:
Myc signaling. For the Myc pathway, sufficiently large
numbers of Myc-associated miRNAs are known to enable
statistical testing of the concordance between the miRNA–
pathway connections predicted by our approach to those
identified by previous studies [3,4,16]. Of 10 miRNAs previously
shown to be induced by Myc, all 10 miRNAs were also predicted
by our approach to be positively correlated to Myc; while
conversely of 8 miRNAs previously shown to be repressed by Myc,
7 were also predicted by our approach to be negatively correlated
to Myc (Figure 2B, p=0.000251, Fisher’s exact test, Table S11).
IFN-signaling. IFN-c protein secretion has been reported to
be increased by hsa-miR-146a [17], while hsa-miR-25 has been
reported to be repressed in airway smooth muscle cells treated
with cytokines IL-1b, TNF-a, and IFN-c [18]. Using our
approach, hsa-miR-146a and hsa-miR-25 were predicted to be
positively and negatively associated with IFN-signaling,
respectively (Figure 2C).
STAT signaling. Two miRNAs (hsa-miR-146a and a EBV-
related miRNA) were predicted by our approach to be positively
associated with STAT signaling. hsa-miR-146a (Figure 2D, labeled
brown) has been reported to modulate STAT3 signaling [19]. The
connection of hsa-miR-146a to both the IFN and STAT pathways
is not unexpected, as hsa-miR-146a has been linked to
inflammatory/immune responses involving both pathways [20].
The correlation of an EBV miRNA (Figure 2D, labeled red) to the
STAT3 pathway may be due to the reported effect of EBV
infection on STAT3 activation [21].
P53 signaling. Our approach identified hsa-mir-29a, hsa-mir-
29b, and hsa-mir-34a* as being positively correlated to p53
signaling. Supporting this interaction, miRNAs of the mir-29
family have been previously reported to activate p53 [5], and hsa-
miR-34a* is the minor sequence of the miR-34a stem-loop which
produces hsa-miR-34, a p53 inducible miRNA [22]. Likewise, we
identified hsa-mir-18a, hsa-mir-19a, hsa-mir-20a and hsa-mir-92a-1* as
being negatively correlated to p53 signaling. These four miRNAs
are part of the miR-17-92 cluster, which is repressed by p53 [23]
(Figure 2E).
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Modulators of Wnt Signaling
We then explored if our approach could identify novel miRNA–
pathway associations not previously reported in the literature. For
this purpose, we focused on the Wnt signaling pathway, since few
miRNAs are known to be associated with Wnt signaling. Among
the 276 miRNAs analyzed, we identified 29 and 18 miRNAs
positively and negatively correlated to Wnt signaling, respectively.
To enrich for miRNAs acting as upstream modulators of Wnt
signaling rather than downstream targets, we considered from this
set only those miRNAs that were a) consistently positively
associated with the Wnt pathway in all the cohorts analyzed
(Figure 3A), and b) whose expression was not affected by a b-
catenin knockdown experiment in AGS gastric cancer cells (see
Methods and Table S12). Using these criteria, 4 miRNAs, hsa-miR-
205, hsa-miR-221, hsa-miR-517c, and hsa-miR-519a (inside orange
rectangle, Figure 3A) were nominated as candidate regulators of
Wnt signaling.
To assess the effects of these four miRNAs on Wnt pathway
activity, we transfected pri-microRNA sequences of hsa-miR-205,
hsa-miR-221, hsa-miR-517c, and hsa-miR-519a into STF-3a cells,
which are HEK293 embryonic kidney cells constitutively express-
ing a TOP-Flash reporter plasmid and overexpressing WNT-3a
[24]. TOP-Flash is a luciferase expressing plasmid containing
multimerized TCF/LEF binding sites, a standard reporter assay
for determining Wnt/b-catenin activity [25]. Compared to control
transfected cells, significantly higher TOP-Flash transcriptional
activities were observed in STF-3a cells transfected with hsa-miR-
205, hsa-miR-221, hsa-miR-517c,o rhsa-miR-519a, ranging from 2-
to 25-fold induction (Figure 3B). To extend our analysis beyond
the artificial TOP-Flash reporter, we generated gene expression
profiles of STF-3a cells transfected with pri-hsa-miR-221, and
explored if endogenous Wnt target genes might be regulated by
this miRNA. Geneset enrichment analysis (GSEA, [26]) of genes
up-regulated in hsa-mir-221 transfected STF-3a cells revealed
significant enrichment of the geneset KENNY_WNT_UP (top
panel, Figure 3C), corresponding to genes up-regulated in HC11
mammary epithelial cells by expression of constitutively active
CTNNB1, a key component of the Wnt pathway [27]. Similarly,
GSEA of hsa-miR-519a-transfected STF-3a cells showed significant
enrichment of the geneset LIN_WNT_UP, comprising Wnt target
genes identified by expression of the Wnt antagonist APC in APC-
deficient SW480 colon cancer cells [28] (bottom panel, Figure 3C).
These two Wnt-related gene sets (KENNY_WNT_UP and
LIN_WNT_UP) were noted because they exhibited the highest
GSEA enrichment scores among all Wnt-related genesets in the
MSigDB C2 collection for hsa-mir-221 and hsa-miR-519a respec-
tively (Tables S13 and S14). The observation that hsa-miR-221 and
Figure 2. Identifying miRNA–pathway connections. A) Pathway and miRNA gene expression signatures are mapped onto gene expression
profiles of samples. For every pathway, positively and negatively correlated miRNAs are identified. This process is repeated across multiple cohorts to
identify robust connections. B) miRNA-Myc connections. Positively and negatively correlated miRNAs to Myc are shown in red and green. Correlated
miRNAs previously reported as Myc-regulated are highlighted in brown (Myc-induced) and blue (Myc-repressed). C) miRNA-IFN-c connections.
Correlated miRNAs previously reported as connected to IFN-c are highlighted. D) miRNA-STAT3 connections. Correlated miRNAs previously reported
as connected to STAT3 are highlighted. E) miRNA-p53 connections. Correlated miRNAs previously reported as regulated by p53 are highlighted.
doi:10.1371/journal.pgen.1002415.g002
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genesets suggests that these two miRNAs may contribute to
distinct Wnt-related regulatory cascades. No increases in TCF/
LEF transcriptional activity were observed when the miRNA
transfections were performed on STF cells not expressing WNT-
3a (data not shown). These results suggest these miRNAs may
modulate Wnt activity, but can only do so in the presence of an
active Wnt ligand. Interestingly, while not achieving significance,
several genes upregulated in the gastric-derived mir-221 signature
were also upregulated in expression profiles of hsa-mir-221
transfected STF-3a cells (positive Normalized Enrichment Score
(NES)=0.84), and several genes downregulated in the gastric-
derived mir-221 signature were also downregulated in the hsa-mir-
221 transfected STF-3a cells (negative Normalized Enrichment
Score (NES)= 21.652) (Figure S2). For mir-519a, we again found
that several genes upregulated in the gastric-derived mir-519a
signature were also found to be upregulated in hsa-mir-221
transfected STF-3a cells (positive Normalized Enrichment Score
(NES)=1.091). Only one gene was downregulated in the hsa-mir-
519a signature, which is insufficient for GSEA analysis. These
results may suggest that certain genes belonging to a miRNA
signature may themselves be directly or indirectly regulated by
that miRNA.
The miRNA–Pathway Network Reveals a High Level of
Functional Redundancy
The availability of an extensive catalog of miRNA–pathway
connections provided us with the opportunity to analyze the global
properties of the miRNA–pathway network. Integrating gene
expression signatures from 276 miRNAs passing the signature
robustness test (see Methods) and 174 pathway signatures
representing 26 oncogenic pathways, we constructed a miRNA–
pathway network of 302 nodes and 12442 edges (Figure 4A, see
Methods for network construction). Here, ‘node’ refers to either a
pathway or miRNA signature, and edges refer to significant
correlations between nodes, which can be either positive (‘‘positive
edges’’) or negative (‘‘negative edges’’).
We found that the miRNA–pathway network is dominated by
positive edges (8327 positive vs. 4115 negative) (Figure 4B), similar
to previously reported gene co-expression networks [29]. miRNA-
Figure 3. Identifying miRNA–Wnt pathway connections. A) Wnt correlated miRNA. Yellow nodes indicate miRNAs, purple nodes indicate
pathways. Color of lines indicate the correlation type (red=positive, green=negative). Thickness of lines indicates frequency of correlation calls
across 5 cohorts. miRNAs with the highest frequency of positive correlation calls to the Wnt pathway are marked with pink circles. miRNAs regulated
by b-catenin are labeled in grey. The gold oval highlights the miRNAs selected for functional testing. B) TCF/LEF transcriptional acitivity in STF-3a cells
transfected with candidate miRNAs. Non-targeting sequences were used as a negative control. (y-axis) TOP-flash reporter activity was measured in
RLU (relative light units). C) Geneset enrichment analysis of miRNA-tranfected cells. Top panel, enrichment plot for the Wnt activation signature
(KENNY_WNT_UP) in miR-221 overexpressing cells. Bottom panel, enrichment plot for the Wnt activation signature LIN_WNT_UP in miR-519a
overexpressing cells. The nominal p-value estimates the statistical significance of the enrichment score for a single geneset. The q-value is the FDR
(false discovery rate), adjusted for gene set size and multiple hypotheses testing among MSigDB (C2 collection, Release 2.5).
doi:10.1371/journal.pgen.1002415.g003
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expected result given the higher number of miRNA nodes
(Figure 4B). Formally, positive edges connecting two miRNAs X
and Y can reflect two different scenarios. In Scenario A, miRNAs
X and Y act independently from one another to exert similar
downstream effects i.e., X and Y exhibit ‘‘redundancy’’. In
Scenario B, miRNA X may regulate miRNA Y, with Y
proceeding to exert the actual downstream effect, or vice versa
(Figure 4D). We sought to determine which of these scenarios
might characterize the miRNA-miRNA edges in the network.
First, we tested if positive miRNA-miRNA edges in the network
might be selectively enriched in members from the same miRNA
family, since same family-miRNAs are known to exhibit
redundant or partially redundant functions [30]. Testing four
different miRNA families (miR-200 family; mir-17 family; miR-30
family; miR-10 family; Table S15) (Figure 4C), we found that that a
miRNA was .5 times more likely to be positively correlated to
another miRNA from the same family, rather than a miRNA from
Figure 4. Functional redundancy in the miRNA–pathway network. A) The miRNA–pathway network. Lines represent significant correlations
across 276 miRNAs and 26 pathways (red=positive, green=negative). Yellow nodes are miRNAs and purple nodes are pathways. B) Number of
positive and negative correlations between different node types (miRNA-miRNA, pathway-pathway, miRNA–pathway). C) Frequency of positively
correlated miRNA pairs within and between miRNA families. A taller column indicates a higher frequency of positive miRNA-miRNA correlations.
miRNA pairs from the same family show a higher frequency of correlations compared to miRNA pairs between different families. D) Possible scenarios
explaining positive correlations between two miRNAs. Scenario A (left) – miRNAs act independently but have common downstream effects
(redundancy); Scenario B (right) – one miRNA directly regulates the second miRNA. (bottom) miRNAs with significant overlaps in target mRNAs
(overlap ratio .0.6) are more likely to be positively correlated compared to miRNAs with small target mRNA overlaps (overlap ratio ,0.4). y-axis:
probability of positive correlation. x-axis: miRNA pairs with overlap ratios of .0.6 or ,0.4. p-values were computed using chi-square test.
doi:10.1371/journal.pgen.1002415.g004
miRNA and Oncogenic Pathway Co-Activation Network
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229, Table
S16), supporting the notion that miRNA-miRNA edges in the
network are likely to identify functionally redundant miRNAs.
We extended our analysis from same-family miRNAs to all
miRNAs in the network. Since functionally-redundant miRNAs
are likely to share significant overlaps of predicted target mRNA
sequences, we used four sequence-based prediction databases
(MiRanda, PicTar, TarScan, and PITA; Table S17) to identify
predicted target mRNAs for 215 miRNAs in the network (78%)
(Figure 4D). We found that miRNAs with significant overlaps in
target mRNAs (overlap ratio.0.6, see Methods) were .2 times
more likely to be connected via positive miRNA-miRNA edges
compared to miRNAs with small target mRNA overlaps (56.25%
vs. 19.67%, p=2.19610
213, Figure 4D, Table S18). These results
suggest that positive miRNA-miRNA edges in the network are
likely to represent miRNA pairs with a high degree of functional
redundancy, as evidenced by their targeting similar sets of
downstream genes.
Oncogenic Signaling Pathways Frequently Target
miRNAs Exerting Similar Downstream Effects
Previous studies have proposed that signaling pathways are
frequently targeted by multiple independent miRNAs (‘miRNA
cotargeting’; [7] (Figure 5A, left). The availability of the miRNA–
pathway network allowed us to investigate the reciprocal
possibility – that oncogenic signaling pathways might also co-
ordinately regulate several miRNAs with similar downstream
effects, which we refer to as ‘‘pathway cotargeting’’ (Figure 5A,
right). To identify candidate miRNAs co-targeted by the same
pathway, we nominated pairs of miRNA where both members
were jointly positively or negatively correlated to the same
common pathway. Of 262 miRNAs in the network significantly
correlated with at least one pathway, 8020 miRNA pairs (out of
.20,000 possible pairs) were candidates for pathway cotargeting,
including hsa-miR-497 and hsa-miR-503 (ER, Ras, and TGF-b),
hsa-miR-20a and hsa-miR-372 (EGFR and p53), and hsa-miR-192
and hsa-miR-215 (BRCA1 and HER2).
Figure 5. Cotargeting of miRNAs by oncogenic signaling pathways. A) Models of miRNA cotargeting and pathway cotargeting. (left) In
miRNA co-targeting, multiple independently acting miRNAs can target the same pathway to modulate pathway activity (right) In pathway
cotargeting, a pathway acts to target multiple independent miRNAs, which exert either similar or distinct downstream effects. B) miRNAs jointly
correlated to a common pathway tend to be expressed from the same genomic cluster. In Scenario 1, a miRNA pair regulating a common pathway is
associated with the same genomic location. In Scenario 2, that miRNA pair occupies different locations.(bottom graph) miRNAs connected to the
same pathway are likely to be transcribed from the same genomic cluster rather than from different genomic clusters. C) miRNAs jointly correlated to
a common pathway tend to exhibit significant overlaps in target mRNAs. Scenario 1 – miRNA pairs jointly correlated to the same pathway tend to
exert similar downstream effects ie high overlap of target mRNAs (overlap ratio .0.6). Scenario 2 – miRNAs pairs jointly correlated to the same
pathway tend to exert distinct effects (overlap ratio ,0.4). (bottom graph) miRNAs with significant overlaps of target mRNAs (overlap ratio .0.6) are
more likely to be jointly connected to the same pathway. p-values were computed from a chi-square test.
doi:10.1371/journal.pgen.1002415.g005
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same pathway are likely to represent miRNAs commonly
regulated by the pathway. Specifically, we found that miRNA
pairs jointly correlated to the same pathway exhibited a strong
preference to be expressed from the same chromosomal region,
suggesting that they may possess common upstream regulators.
Examining genomic clusters of commonly transcribed miRNAs
[31], we found that miRNA pairs located in the same genomic
cluster were twice as likely to be jointly correlated to the same
pathway compared to miRNA pairs transcribed from different
genomic clusters (80.95% vs. 38.54%, p=8.22610
28, chi-square
test) (Figure 5B, Table S19). For example, hsa-miR-18a and hsa-
miR-19a, which are transcribed at a miRNA cluster at 13q31.3,
were jointly correlated to EGFR, IFN-c, Myc, and p53. Indeed,
these miRNAs have also been independently shown to be co-
regulated by Myc signalling [16]. As another example, hsa-miR-
154 and hsa-miR-377 located at 14q32.31 were jointly correlated to
Myc, TGF-b, and VEGF pathways. The frequent occurrence of
genomic co-localization (thereby assuming common upstream
regulation) within miRNA pairs jointly correlated to the same
pathway makes it likely that these miRNA pairs are co-regulated
by the same pathway.
miRNAs exhibiting joint correlations with common pathways
were also highly enriched in miRNA pairs exhibiting significant
overlaps in predicted target mRNAs (overlap ratio.0.6) relative to
miRNA pairs with small target mRNA overlaps (73.44% vs
35.08%, p=1.4610
210) (Figure 5C, Table S20a). This result
suggests that miRNAs jointly correlated to a pathway tend to exert
similar downstream effects. The high overlaps in predicted target
mRNAs are unlikely to be explained by high levels of sequence
similarity between miRNA pairs, since a control analysis using
only miRNAs with pairwise sequence similarity scores of less than
-5 (see Methods) yielded similar results (67.86% vs. 35.54%,
p=0.000357, Table S20b). Notably, some of those downstream
effects may involve feedback activation or inhibition of the
pathway itself.
The miRNA–Pathway Network Exhibits a Small-World
Modular Organization and Is Densely Interconnected
Finally, we expanded our analysis of the miRNA–pathway
network to consider its global topological and network features.
The term ‘‘small-world network’’ has been previously used to refer
to a network organization that is highly clustered with small path
lengths (average lengths of the shortest path connecting any two
nodes). Examples of previously known small-world networks are
neural circuits of the vertebrate brain [32], the power grid of the
western United States, and the collaboration graph of film actors
[33]. Our topological analysis suggests that the miRNA–pathway
network is also likely to exhibit a small-world organization.
Comparing topological features of the miRNA–pathway network
to an equivalent random graph with the same number of nodes
and degree, we found that the miRNA–pathway network fulfils
two key prerequisites for a small-world network [33], referred to as
Ls .=L r and that Cs..Cr. First, the characteristic path length of
the miRNA–pathway network, LmicroRNA2path, is 1.7822, which is
almost equal to, but greater than the characteristic path length for
an equivalent random graph network, Lrand=1.724160.0008
(mean6std from 1000 permutations, see Methods). Second,
the clustering coefficient of the miRNA–pathway network,
CmicroRNA2path=0.6351, is more than twice the clustering
coefficient of the equivalent random graph network,
Crand=0.270560.0013. For networks with small node numbers
of nodes (,200–3000, miRNA–pathway network: 302 nodes), the
observation that CmicroRNA2path.Crand is sufficient to demonstrate
small-world properties [34].
This result also indicates that the miRNA–pathway network is
more than twice as modular compared to an equivalent random
graph, since the clustering coefficient Cs is a measure of potential
network modularity. Analyzing the miRNA–pathway network
presented in Figure 4A, we found that the miRNA–pathway
network is coherently structured in a strongly modular manner,
with at least two major modules and two smaller modules
(Figure 6A, left panel). In comparison, a simulated hierarchical
network of the same size exhibited a higher number of modules
(.20) that were distinctly smaller compared to the miRNA–
pathway modules (Figure 6B, right panel). An even mix of
miRNAs and pathways were localized to each module (Figure 6A,
left panel).
Besides being small world, genetic and metabolic networks such
as protein-protein interaction and yeast transcriptional or gene
regulatory networks have also been shown to be ‘‘scale-free’’,
where the majority of connections are dominated by a small
number of nodes (‘‘hubs’’) [35,36]. To ask if the miRNA–pathway
network might obey a scale-free character, we analyzed the degree
distribution plot of the miRNA–pathway network, which charac-
terizes the probability of a node having a certain number of
neighbors. Strikingly, instead of obeying a power law, most of the
connections in the miRNA–pathway network are of the many-to-
many type (Figure 6B, left panel). Specifically, .98% of nodes in
the miRNA–pathway network have more than 10 neighbors
(Figure 6B, left panel), compared to only 1.7% in a simulated
network typical of gene regulatory and metabolic networks (see
Methods) (Figure 6B, right panel). This result suggests that the
miRNA–pathway network is not scale-free. This result may be
related to the observation that the miRNA–pathway network
comprises mostly miRNAs that can regulate multiple pathways,
and which are in turn regulated by multiple pathways. In other
words, the miRNA–pathway network is primarily comprised of
regulators. This observation is further pursued in the Discussion.
Discussion
In this study, we have described a general approach for
generating gene expression signatures which can be used to infer
patterns of miRNA expression. Validation of this approach was
demonstrated in both a training set and also an independent test
set of gastric cancer samples. The member genes in the miRNA
gene expression signature, while comprising genes transcription-
ally altered as a consequence of miRNA activity, may not
necessarily be direct miRNA target genes. This feature distin-
guishes our study from previous studies using sequence-predicted
miRNA target genes to annotate miRNA functions. To our
knowledge, our study is the first to demonstrate the ability of gene
expression signatures to act as surrogates of miRNA activity.
While the current analysis is limited to 276 miRNA signatures
passing various quality and significance threshold cutoffs, applying
this strategy to larger and more generalized training sets will
undoubtedly identify more miRNA signatures. The current work
should thus be regarded a proof-of-concept on the feasibility of
gene expression signatures as surrogates of miRNA expression.
Using gene expression signatures to predict miRNA activity
may address two major limitations currently facing miRNA–
pathway discovery efforts – cost and scalability. Currently, most
available experimental platforms (e.g., microarrays, deep sequenc-
ing) require the use of separate analytical assays to generate
miRNA and mRNA information for a single sample (e.g., different
microrarrays, or different RNA isolation techniques), increasing
miRNA and Oncogenic Pathway Co-Activation Network
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possible to analyze both miRNA and pathway activity patterns
using a single common platform of gene expression. Moreover,
because only gene expression information is required once the
miRNA signature is known, any sample cohort for which gene
expression (mRNA) data is available can be analyzed, without the
requirement for companion miRNA data. This strategy thus opens
up the availability of the thousands of publicly available
microarray data sets for the discovery of new miRNA–pathway
connections. Notably, we found that many of the miRNA
signatures could recapitulate patterns of actual miRNA expression
in a variety of different tumor types. This may not be too
surprising, as it is conceptually similar to studies where gene
expression signatures linked to pathways or drugs have been
shown to exhibit broad applicability even in tissues distinct from
those where the original signatures were derived (eg [14], [37]).
However, we emphasize that our study does not rule out the
possibility that miRNAs may exert tissue-specific effects.
One immediately useful application of miRNA gene expression
signatures lies in identifying novel miRNAs linked to canonical
signalling pathways. Using the miRNA–pathway network con-
structed in this study, we confirmed a host of previously reported
miRNA pathway interactions, and identified four miRNAs as new
candidate Wnt modulators (hsa-miR-205, hsa-miR-221, hsa-miR-
517c, hsa-miR-519a). Experimental evidence supporting that these
miRNAs are indeed Wnt regulators was also provided using cell
line transfections, reporter assays, and gene expression profiling.
Our study thus provides a large resource of potential pathway-
modulating miRNAs for a variety of pathways which can be
further tested by researchers. The information provided by this
study is unlikely to be duplicated by other studies attempting to
relate specific miRNAs to pathways and processes, as these
previous studies have primarily relied on sequence-based miRNA
target predictions, which have high false positive rates [10] and a
general lack of tissue context – i.e., sequence-matches between a
miRNA and a collection of mRNAs does not guarantee that the
miRNA is indeed coexpressed with the target mRNA in the same
cell type or tissue.
Besides miRNA interactions with individual pathways, our work
reveals that co-expressed miRNAs are likely to exhibit a high
degree of functional redundancy in targeting similar sets of
downstream genes, and that signalling pathways may frequently
cotarget multiple independent miRNAs with similar downstream
effects. This observation extends previous studies [7] reporting the
widespread existence of multiple pairs of miRNAs which target
common genesets. Our observation that pathways frequently
cotarget multiple miRNAs provides further evidence that miRNAs
rarely act singly and almost always act in combinations to
modulate cellular behaviour. The role of miRNAs as broad
modulators may also explains the selection pressure for functional
redundancies [30].
The functional role of miRNAs as broad modulators of cellular
activities, rather than activators or repressors of specific genes, also
explains the large modularity and non-scale-free attributes of the
miRNA–pathway network, revealed by global topological analysis
[1,2]. The non-scale-free nature of the network is also likely
explained by the membership of the network itself. Compared to
the membership of typical scale-free genetic networks such as gene
regulatory networks (GRNs) comprising a few master regulators
and downstream effectors, the miRNA–pathway network is
Figure 6. miRNA–pathway network topology. (A) Topological overlap matrix of the miRNA–pathway network (left) and a simulated network
(right) of the same size but with a hierarchical, scale-free and modular architecture typical of gene regulatory and metabolic networks. Each row and
column corresponds to a node. Rows and columns were ordered using unsupervised hierarchical clustering, Nodes that have large topological
overlap are placed close together, resulting in modules of nodes. miRNAs and pathways nodes are indicated by red or green bars, respectively.
(B) Degree distribution plots of the miRNA–pathway network (left) and a simulated network (right) of the same size but with a hierarchical, scale-free
and modular architecture typical of gene regulatory and metabolic networks. y-axis: log frequency of nodes having the degree k, x-axis: log k.
doi:10.1371/journal.pgen.1002415.g006
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implication of the small-world but non-scale-free architecture is
greater resilience to targeted ‘‘hits’’ than scale-free networks.
Scale-free networks are resilient to randomly placed damage or
failure, but susceptible to targeted attacks on the hubs (the few
highly connected nodes), since such hits would remove a
disproportionate amount of the links in the network [38]. The
oncogenic miRNA–pathway network, with its small-world but
non-scale-free architecture, does not rely on a few highly
connected hubs, but spreads its ‘‘risk’’ across the many
interconnected nodes (especially miRNAs). The implications of
this finding on attempts to perturb cell function using miRNAs
deserve further study.
In conclusion, our finding that gene expression signatures can
capture miRNA activity is in general agreement with proposals
that many cellular perturbations (e.g., responses to extracellular
ligands, disease states, gene mutations) are likely to cause
transcriptomic changes, and that these perturbations can be
captured using gene expression signatures. Because functionally
significant perturbations are certainly not limited to miRNAs and
pathways alone, but can also include other genetic factors (SNPs,
copy number variations, and mutation status) and epigenetic
factors (e.g., DNA methylation and histone modification), there is
in principle no reason why similar strategies could not be used to
represent these other factors as well. Using gene expression
signatures as a ‘‘common currency’’, it may thus be possible to
integrate multiple types of cellular perturbations into a common
network, as we have done for miRNAs and pathways in this study.
This may prove a powerful approach to identify functionally
relevant relationships across a host of molecular levels that
ultimately constitute the disease regulatory landscape.
Materials and Methods
Cell Lines and Primary Clinical Specimens
GC cell lines AGS, Kato III, SNU1, SNU5, SNU16, NCI-N87,
and Hs746T were obtained from the American Type Culture
Collection. AZ521, Ist1, TMK1, MKN1, MKN7, MKN28,
MKN45, MKN74, Fu97, and IM95 cells were obtained from
the Japanese Collection of Research Bioresources/Japan Health
Science Research Resource Bank and cultured as recommended.
SCH cells were a gift from Yoshiaki Ito (Institute of Molecular and
Cell Biology, Singapore) and were grown in RPMI media. YCC1,
YCC3, YCC6, YCC7, YCC10, YCC11, and YCC16 cells were a
gift from Sun-Young Rha (Yonsei Cancer Center, South Korea)
and were grown in MEM supplemented with 10% fetal bovine
serum (FBS), 100 units/mL penicillin, 100 units/mL streptomycin,
and 2 mmol/L L-glutamine (Invitrogen). In total, 39 unique GC
cell lines, 2 fibroblast cell lines, and 1 normal gastric epithelial cell
line (HFE145) were profiled. Wnt activity was assessed using STF-
3a cells, which are HEK293 cells engineered to stably express
WNT3A and a SuperTopFlash (STF) reporter gene [24]. Primary
gastric tumors were obtained from the Singhealth Tissue
Repository, an institutional resource of National Cancer Centre
of Singapore and Singapore General Hospital. All patient samples
were obtained with informed patient consent and approvals from
Institutional Review Boards and Ethics Committees.
miRNA and Gene Expression Profiling
Gastric cell lines and primary tumors were profiled using
Human miRNA (V2) Microarrays (Agilent) and Affymetrix
Human Genome U133 plus Genechips (HG-U133 Plus 2.0,
Affymetrix). Where multiple probes existed for a unique miRNA,
we took the probe providing the highest variance across samples as
representative of that miRNA. The miRNA and gene expression
data used in this manuscript can be accessed from the Gene
Expression Omnibus (GEO) under accession numbers GSE22183
(miRNA, cell lines), GSE23739 (miRNA, primary tumors),
GSE15459 (mRNA, primary tumors), GSE2990 (mRNA, 189
breast tumors), and GSE2034 (mRNA, 286 breast tumors). For
independent validations, we used a breast cancer data set
(GSE19783, mRNA and miRNA datasets analyzed using series
matrices provided at GEO), and the TCGA ovarian cancer and
glioblastoma data sets (http://tcga-data.nci.nih.gov/tcga/tcga-
Home2.jsp; Ovarian: Level 2 datasets (mRNA (U133A) and
miRNA (Agilent V2); Glioblastoma: Level 2 datasets (mRNA
(U133A) and miRNA (Agilent V1)). Only samples having both
mRNA and miRNA profiles associated with the 276 miRNA
gastric-derived signatures were included in analysis. We also
analyzed a signature based on genes differentially expressed in hsa-
miR-155-transfected HEK-293 cells (compared to control, nom-
inal p,0.0005 using LIMMA; GSE9264) [39].
Robustness of miRNA Gene Expression Signatures
To assess the robustness of a miRNA signature, permutation
tests were performed where the labels of profiles belonging to the
‘‘miRNA high group’’ and the ‘‘miRNA low group’’ were
randomly shuffled 1000 times, and the number of differentially
expressed genes between the two permuted groups were counted
(permuted signature size). The number of times the permuted
signature size exceeded the actual signature size over N=1000
was taken as the False Discovery Rate (FDR) representing the
probability that the signature is not robust (the null hypothesis). A
FDR ,5% threshold was used in this study to select signatures for
further analysis. 276 signatures remained after the signature
robustness permutation tests were performed on the original 516
miRNA signatures identified in the discovery set.
Correlations between miRNA Signature Expression
Scores and Actual miRNA Expression Values
miRNA signatures were deemed to be significantly correlated to
actual miRNA expression if a signature was both positively
correlated to the miRNA (Spearman’s correlation R.0) at a
threshold q-value of ,0.25, where the q-value denotes the
significance of the correlation. To compute the q-value of a
miRNA signature, we first obtained a nominal p-value represent-
ing the significance of the Spearman correlation coefficient
between the miRNA signature score and actual miRNA
expression. This nominal p-value was then corrected for multiple
comparisons using the R function p.adjust, with method option set
to ‘‘BH’’ [40], yielding a final q-value. We also used permutation
tests to assess the global significance of an observed proportion of
miRNA expression signatures positively correlated to actual
miRNA expression in the validation data sets. Here, we randomly
scrambled the miRNA labels of the miRNA expression signatures
10,000 times, and counted the number of times that percentage of
randomized miRNA gene expression scores positively correlated
to actual miRNA expression data exceeded the actual data. The
value was used as a nominal p-value with which to accept (p.0.05)
or reject the null hypothesis (p,0.05), the null hypothesis being
that a random miRNA signature is able to predict the expression
of a specific miRNA X as accurately as the miRNA X signature
itself.
miRNA–Pathway Network Construction
miRNA and pathway gene expression signatures were mapped
onto individual cancer samples using a previously-described
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(miRNA or pathway) a rank-based, non-parametric method was
used to compute a score for each sample representing the
‘activation’ state of that signature. A detailed description of this
method is provided in Text S1. Gene expression signatures
(n=174) were obtained from MSigDB (Table S5 provides
signature details), and further summarized into 26 major
oncogenic pathways reflecting oncogenesis and the tumor
microenvironment (see Table S6 for the 26 pathways and the
signatures representing them). For the network construction, we
only selected those MSigDB C2 signatures representing 26
pathways - This was specifically done to focus our analysis of
those pathways relevant to cancer (Akt, Myc, etc), while
eliminating from analysis those pathways that were either not
related or peripherally related (eg signatures related to heart
disease). Significant miRNA–pathway, miRNA-miRNA, and
pathway-pathway associations were identified by computing
Spearman correlation coefficients (either positive or negative)
between the expression/activation scores of each signature pair
across the cohort. Because the 26 pathways are summarized from
multiple individual signatures, associations involving pathways and
a second entity (e.g., a miRNA or another pathway) were only
retained when they met the following criteria: at least one
signature in the pathway must be significantly positively or
negatively correlated with the second entity, and no significantly
discordant correlations among the remaining individual signatures
are observed. All p-values were corrected for multiple hypothesis
testing [41]). Spearman correlations with a corresponding
FDR,0.05 were considered. The network associations were
iteratively applied to five cancer cohorts: 39 gastric cancer cell
lines (‘‘GCCL’’, subset of the training gene expression dataset),
200 primary gastric tumors (‘‘SG GC’’), 70 primary gastric tumors
(‘‘AU GC’’), 189 primary breast tumors (‘‘Sotiriou Breast’’), and
286 primary breast tumors (‘‘Wang Breast’’). Any associations
observed to be discordant across any two of the five cohorts were
discarded.
Experimental Validation of Wnt-Related miRNAs
To identify candidate miRNAs regulated by b-catenin knock-
down after 24h or 48h b-catenin siRNA treatment, control and b-
catenin siRNA treated cells (24h, 48h) were profiled on Human
miRNA microarrays (V2) (Agilent). Three independent replicates
were compared to identify differentially regulated miRNAs. To
measure effects of hsa-miR-205, hsa-miR-221, hsa-miR-517c, and
hsa-miR-519a on Wnt activity, TOPFLASH assays were conducted
on STF-3A cells transfected with these miRNAs as as previously
described [42]. All experiments were repeated three independent
times. Gene expression profiling using Affymetrix Human
Genome U133 plus Genechips (HG-U133 Plus 2.0, Affymetrix)
were also performed on pri-hsa-miR-221 and pri-hsa-miR-519a
transfected STF-3A cells. Expression profiles were processed using
MAS5.0 (R/Bioconductor), log10 transformed, median centered,
and subjected to ComBat [43] for batch effect elimination.
Geneset Enrichment Analysis (GSEA) was run on the processed
dataset using the C2 (curated genesets) subset of MSigDB (Release
2.5). The Wnt-related genesets with the most significant
enrichments are discussed, and the complete lists of ranked
genesets are provided in Tables S13 and S14.
Predicted Target mRNAs and Sequence Similarity
Analysis
Predicted target mRNAs for the 276 microRNAs analyzed in
this study were obtained by combining data from four prediction
databases: MiRanda, PicTar, TarScan, and PITA. The final set of
predicted target mRNAs for a microRNA is the union of the sets of
predicted target mRNAs from all four prediction databases. Here,
we chose to use the union rather than the intersect of the various
target prediction programs because considering the latter would
limit our analysis to only those miRNAs contained in the four
databases, which would severely confine subsequent analysis. We
used genes (as defined by HUGO symbols) as the basic unit of
target mRNAs. Details of the sources for the predicted target
mRNAs are available in Table S17. Overlap ratios between the set
of target mRNAs for miRNA X, SX, and the set of target mRNAs
for miRNA Y, SY, were computed as follows: Overlap ratio =
|(SX > SY)|/min(|SX|, |SY|). miRNA sequence information was
obtained from ftp://mirbase.org/pub/mirbase/CURRENT/
mature.fa.gz and sequence similarity scores between pairs of
microRNAs were computed using the pairwiseAlignment function
from Bioconductor package Biostrings. To eliminate microRNA
pairs with close sequence similarity, we retained only microRNA
pairs with pairwise sequence similarity scores of less than -5. (The
sequence similarity score for an identical pair of miRNAs would
be 0.)
Network Models
Random graph networks were generated using the Erdos-Renyi
model [44], where all possible pairs of N=302 nodes were
connected with probability p=1 and an initial node degree of
kinitial= 44, such that the resulting random graph is equivalent to
the miRNA–pathway network in terms of numbers of nodes (302)
and mean degree (81.330360.2537 for 1000 generated random
networks compared to 82.397 for the miRNA–pathway network).
Each pairwise correlation was considered as a two-way interaction
and no self-correlations were assumed in the microRNA-pathway
network. Clustering coefficients for individual nodes i were defined
as Ci =2 n/ki(ki -1 ), where n denotes the number of direct links
connecting the ki nearest neighbors of node i [33]. The clustering
coefficient for a network S, CS, is the mean of Ci over all nodes i in
the network S and is a measure of the potential modularity of S.
Hierarchical scale-free networks (HSFN) were generated using a
slightly modified version of a previously outlined iterative
construction algorithm [45]. Briefly, a 4-level HSFN was first
built using a fully connected cluster of 4 nodes as the basic
construction unit. Then, a 2-level HSFN was built using a fully
connected cluster of 7 nodes as the basic construction unit. The
outer nodes of the outer clusters at the second level of the 2-level
HSFN were then connected to the central node of the 4-level
HSFN, in a manner similar to the second level of the 4-level
HSFN itself to that central node. We then eliminated 3 of the
outer nodes of the 2-level HSFN so that the final HSFN was
exactly of the same size as the microRNA-pathway network (302
nodes). The degree of topological overlap between two nodes i and
j, OT(i, j), was computed as [#Common neighbors(i, j)]/
[min (ki,k j)], where ki,k j are the degrees of node i and node j,
respectively.
Other Statistical Analysis and Visualization Methods
P-values denoting the significance of a corresponding Spearman
correlation coefficient R between two N-element vectors were
estimated from the Student t-distribution, against the null
hypothesis that the observed value of t=R/![(12R
2)/(N–2)]
comes from a population in which the true correlation coefficient
is zero. Hierarchical clustering and heatmap displays were
conducted using BioConductor packages gplots and RColorBrewer,
using default parameters, a Euclidean distance metric and
complete linkage.
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Figure S1 Distribution of Spearman correlation coefficients (R)
and q-values (corrected p-values, see Methods) in permuted data.
The graphs represent one permutation set randomly chosen from
10,000 permutations. The numbers of miRNAs passing the R.0,
q,0.25 treshold is shown for the A) gastric, B) breast, C)
glioblastoma, and D) ovarian cohorts.
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Figure S2 GSEA of miRNA-tranfected cells using gastric-
derived miRNA signatures. A) Enrichment plots for the gastric-
derived mir-221 signature. (left) Enrichment plot for genes
upregulated in the gastric-derived mir-221 signature, queried
against genes upregulated in miR-221 transfected cells. (right)
Enrichment plot for genes downregulated in the the gastric-
derived mir-221 signature, queried against genes downregulated in
miR-221 overexpressing cells. B) Enrichment plots for the gastric-
derived mir-519a signature (left) Enrichment plot for genes
upregulated in the gastric-derived mir-519a signature, queried
against genes upregulated in miR-519a transfected cells.upregu-
lated portion of the gastric-derived mir-519a signature in miR-
519a overexpressing cells.
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derived hsa-miR-155 signature for a) glioblastoma and b) ovarian
cancer cohorts.
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similarity and reproducibility between sample cohorts for
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ibility. Correlations were computed between pairs of 6906690
matrices. Each matrix represents a sample cohort and contains the
correlation coefficients among 174 pathway and 276 miRNA
signatures.
(DOC)
Table S9 Predicted miRNA–pathway associations.
(XLS)
Table S10 Top 50 miRNAs targeting multiple pathways.
(XLS)
Table S11 Contingency matrix for Fisher’s exact test against the
null hypothesis that there is no concordance between previously
reported mode of Myc action on the miRNAs (activating or
repressing) and the sign of predicted Myc-miRNA correlations
(positive or negative). miRNAs positively (negatively) correlated to
Myc in the miRNA–pathway network are likely to be previously
reported to be Myc-induced (-repressed).
(DOC)
Table S12 Wnt Associated miRNAs: Frequency of Correlations
and Regulation by b-catenin.
(XLS)
Table S13 GSEA report for mir-221 transfected STF-3a cells.
(XLS)
Table S14 GSEA report for mir-519a transfected STF-3a cells.
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Table S15 Membership of miRNA families used as examples for
analysis in Figure 4C.
(DOC)
Table S16 Confusion matrix for chi-square test against the null
hypothesis that there is no correlation between miRNA pairs being
positively correlated and whether they are from the same family or
different families. miRNAs that are from the same family are more
likely to be positively correlated than miRNAs from different
families.
(DOC)
Table S17 Sources of predicted target mRNAs of the miRNAs.
(DOC)
Table S18 Contingency matrix for chi-square test against the
null hypothesis that there is no correlation between miRNA pairs
being positively correlated and whether the overlap ratio of their
common targets is large (.0.6). miRNAs that are positively
correlated to each other are more likely to have large overlap of
target mRNAs (overlap ratio greater than 0.6) compared to
miRNAs that are not positively correlated to each other. miRNAs
with large overlaps of target mRNAs (overlap ratio greater than
0.6) are more likely to be positively correlated than miRNAs with
small overlap of target mRNAs.
(DOC)
Table S19 Contingency matrix for chi-square test against the
null hypothesis that miRNA–pathway interactions are not
associated with the genomic cluster of the miRNAs. miRNA pairs
transcribed from a common genomic cluster are twice as likely to
co-interact with at least one common pathway as miRNA pairs
transcribed from different clusters.
(DOC)
Table S20 Confusion matrix for pathway cotargeting. (A) Chi-
square test against the null hypothesis that miRNA–pathway
interactions are not associated with the number of predicted
mRNA targets. miRNA pairs with large overlaps in predicted
target mRNAs are twice as likely to co-interact with at least one
common pathway as miRNA pairs with small overlaps in targets.
(B) Previous analysis repeated but retaining only miRNA pairs
with pairwise sequence similarity score of less than -5, to remove
sequence similarity as a confounding factor.
(DOC)
Text S1 Computation of pathway activation scores.
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